Featured Research

from universities, journals, and other organizations

Probability of surviving nine types of cancer analyzed

Date:
July 15, 2010
Source:
FECYT - Spanish Foundation for Science and Technology
Summary:
Epidemiologists have presented information on survival of nine types of cancer in Spain and have compared it with other European countries. At five years from diagnosis, the lowest survival rate is observed in lung cancer (less than 11 percent), and the highest in testicular cancer (95 percent). Cancer survival in Spain is at the European average.

Epidemiologists have presented information on survival of nine types of cancer in Spain and have compared it with other European countries.  At five years from diagnosis, the lowest survival rate is observed in lung cancer (less than 11 percent), and the highest in testicular cancer (95 percent). Cancer survival in Spain is at the European average.

"The innovative factor contributed by our work is its relevance to population and measurement of relative survival, which enables us to discover survival related to cancer in a more precise way," María Dolores Chirlaque, main author of the study and researcher in the Epidemiology Service of the Department of Health and Consumption in Murcia, said.

The investigation, which has been published in the journal Annals of Oncology, involved the participation of eight Spanish regions which currently hold a population record of cancer (Basque Country, Navarra, Girona, Tarragona, Castellón, Albacete, Murcia and Granada). It shows all the cases of cancer diagnosed between 1995 and 1999 (57,622), their monitoring until December 2004, and their prognosis.

The results enable us to understand the situation and survival five years after the diagnosis of eight malignant tumours in Spain (breast, lung, colon, rectum, prostate, ovary, testicle, melanoma and Hodgkin's lymphoma).

"When compared to the survival average in Europe, Spain is very close to the European average for the nine tumours studied, with differences less than 2%," highlights the researcher. The highest survival rate for most of the tumours is observed in Finland, Sweden, Norway and Iceland. On the other hand, the lowest corresponds to the Czech Republic, Poland and Slovenia.

As for Spain, the greatest differences have been detected in lung cancer (12.4% in Navarra as opposed to 6.1% in Granada), and the smallest, in breast cancer (91.3% in Castellón versus 81.2% in Albacete). [*More information in the table attached].

Survival percentages

"In the past cancer was considered to be fatal. However, nowadays it has come to be recognised as a curable illness," Chirlaque points out. "Testimony to this is the results shown in this study, which indicate that of every four people who suffer from it (with the exception of lung cancer), more than three overcome it."

  1. Breast cancer, the most common tumour in women, presents a high survival percentage: 83% of patients have survived this type of cancer after five years.
  2. Lung cancer is one of the most aggressive tumours and survival after five years is very low: only 10% of patients diagnosed with a malignant neoplasm survive for more than five years.
  3. Colorectal cancer (of the colon and rectum), the most common malignant tumour if we group men and women together, presents an average survival rate of 50-55% five years after diagnosis, meaning that half the patients survive this form of cancer.
  4. Prostate cancer, today the most common tumour in men, has an increasingly favourable prognosis, with a global survival rate of 76%, which is higher in young adults.
  5. Ovarian cancer presents a very varied prognosis depending on age: whilst 70% of the group between 15 and 44 years survives this form of cancer, this is the case for only 19% of those over 74 years-old.
  6. Testicular cancer, a rare malignant tumour that mainly affects middle-aged males, is the tumour with the best prognosis, with a 95% survival rate five years after diagnosis.
  7. Skin melanoma displays one of the highest survival rates, reaching values over 85%, although there are European countries where recovery exceeds 90%.
  8. Hodgkin's lymphoma displays high recovery with survival greater than 92% amongst young people, although amongst elderly groups it fails to reach 50%.

Story Source:

The above story is based on materials provided by FECYT - Spanish Foundation for Science and Technology. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. D. Chirlaque, D. Salmeron, E. Ardanaz, J. Galceran, R. Martinez, R. Marcos-Gragera, M. J. Sanchez, A. Mateos, A. Torrella, R. Capocaccia, C. Navarro. Cancer survival in Spain: estimate for nine major cancers. Annals of Oncology, 2010; 21 (Supplement 3): iii21 DOI: 10.1093/annonc/mdq082

Cite This Page:

FECYT - Spanish Foundation for Science and Technology. "Probability of surviving nine types of cancer analyzed." ScienceDaily. ScienceDaily, 15 July 2010. <www.sciencedaily.com/releases/2010/07/100715111428.htm>.
FECYT - Spanish Foundation for Science and Technology. (2010, July 15). Probability of surviving nine types of cancer analyzed. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/07/100715111428.htm
FECYT - Spanish Foundation for Science and Technology. "Probability of surviving nine types of cancer analyzed." ScienceDaily. www.sciencedaily.com/releases/2010/07/100715111428.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins